Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo

Encorafenib (LGX818, trade name Braftovi), a novel BRAF inhibitor, has been approved for the treatment of melanoma and colorectal cancer. In the present work, we evaluated encorafenib’s possible antagonistic effects on the pharmacokinetic mechanisms of multidrug resistance (MDR), as well as its perp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Vagiannis, Dimitrios, Budagaga, Youssif, Sabet, Ziba, Hanke, Ivo, Rozkoš, Tomáš, Hofman, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785850/
https://www.ncbi.nlm.nih.gov/pubmed/36559089
http://dx.doi.org/10.3390/pharmaceutics14122595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785850/
https://www.ncbi.nlm.nih.gov/pubmed/36559089
http://dx.doi.org/10.3390/pharmaceutics14122595

Ejemplares similares